BSH 2018 | The TAMARIN study: tamoxifen for MPNs
An upcoming study is investigating a new therapeutic strategy for the treatment of myeloproliferative neoplasms (MPNs). In this interview, Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, UK, gives an overview of the TAMARIN study (ISRCTN65011803); a study supported by Bloodwise’s Trials Acceleration Programme (TAP), investigating the effects of the anti-estrogen therapy tamoxifen on JAK/CALR mutant allele burden and disease course in patients with MPNs. Prof. Harrison highlights the rationale and design of this upcoming study. This video was recorded at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting in Liverpool, UK.
Get great new content delivered to your inboxSign up